Avandia Can Be Saved With New Warnings and REMS, Advisory Cmte. Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Twenty of 33 committee members vote to keep rosiglitazone on the market, with most favoring stronger labeling and restrictions on prescribing.